Back to search results

A Study of Brenipatide for Overweight or Obesity

This study is testing a drug called brenipatide (LY3537031) in healthy people who are overweight or have obesity. Researchers want to see how different doses of brenipatide, given as shots under the skin, work and how safe they are. You might be able to join if you are between 18 and 65 years old, have a body mass index (BMI) between 27.0 and 45.0, and haven't had a big weight change recently. The main way they will measure success is by looking at the percentage of body weight change at Week 1 and Week 29. This study is looking for about 150 participants, but its current status is unclear.

Study design
This is an interventional study involving about 150 participants. Some participants will receive brenipatide, and others will receive a placebo (an inactive substance).
What's involved
Participation in this study will last about 42 weeks. You will receive subcutaneous (under the skin) injections.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome of body weight change will be measured at Week 1 and Week 29.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07476118

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

Active, Not Recruiting
PHASE1Ages 18–65InterventionalBasic science
Eli Lilly and Company
~150 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:BrenipatidePlacebo

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent Change in Body Weight
Measured over Week 1, Week 29

Conditions

Obesity
Overweight

Explore related trials

ObesityOverweight

Where it's being run

3 sites across 3 states
Florida1
Texas1
Wisconsin1

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease, as determined by medical evaluation
Have a BMI within the range of 27.0 to 45.0 kilogram per square meter (kg/m\^2)
Have no significant (not more than 5 percent \[%\]) self-reported weight gain or loss in the past 3 months prior to screening

Exclusion

Have significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, dermatological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination; constituting a risk when taking the Investigational Medical Product (IMP); or interfering with the interpretation of data
Have a prior diagnosis of type 1 or type 2 diabetes mellitus
Have a history of acute or chronic pancreatitis
Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
Have received a glucagon-like peptide-1 (GLP-1) receptor agonist, glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, GIP/GLP-1/glucagon receptor agonist, or amylin receptor agonist within 6 months prior to screening
Have been treated with prescription and over-the-counter medications, or alternative remedies (including herbal/nutritional supplements), that promote weight loss within 6 months prior to screening
Are pregnant or lactating

What this trial measures

  • Percent Change in Body WeightWeek 1, Week 29